☆ 4.2 Review

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective

Thomas J. Herzog et al.

Summary: PARP inhibitors have shown clinical activity in patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic cancers. The sensitivity to PARPi is not only limited to tumors with BRCA mutations but also observed in tumors with HRD phenotype. Regulatory agencies have approved companion and complementary diagnostics to facilitate patient selection for PARPi treatment. This review aims to summarize the biological basis, clinical validation, and clinical relevance of diagnostic methods and assays to assess HRD.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy

Nghia T. Nguyen et al.

Summary: This review article summarizes the development and preclinical evaluation of radioactively-labelled PARP inhibitors for various applications, such as patient selection, response prediction, and tumor diagnosis. It also discusses the latest developments in PARP-targeted radiotherapy and synthetic strategies for large-scale production and clinical translation. The importance of PARP inhibitors in cancer treatment and imaging is highlighted.

CANCERS (2022)

Add to Collection

Article Oncology

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Jung-Min Lee et al.

Summary: The efficacy, safety, and tolerability of cediranib plus olaparib were investigated in patients with platinum-resistant recurrent ovarian cancer. The combination therapy showed some clinical activity in heavily pretreated, non-gBRCAm patients, highlighting the need for further biomarker studies.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Bradley J. Monk et al.

Summary: The study aims to evaluate the efficacy of PARP inhibitor rucaparib and immune checkpoint inhibitor nivolumab in the treatment of newly diagnosed ovarian cancer patients, as well as the effectiveness of their combined use.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Add to Collection

Article Oncology

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Gennaro Daniele et al.

Summary: The study investigated the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab. Results showed that the progression-free survival and overall survival were 20.8 months and 41.1 months, respectively. Clinical factors such as performance status, stage, and residual disease after primary surgery were significant predictors of survival outcomes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Add to Collection

Review Oncology

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Alice Indini et al.

Summary: Patients with platinum-resistant ovarian cancer have a poor prognosis with limited treatment options. While single-agent immunotherapy has shown disappointing results, combining immunotherapy with target therapies like PARP inhibitors and TKIs appears promising. Ongoing trials are evaluating these combination strategies to assess their impact and cost-effectiveness.

CANCERS (2021)

Add to Collection

Review Oncology

Immunotherapy for platinum-resistant ovarian cancer

Giorgio Bogani et al.

GYNECOLOGIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis

Han Gong et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Add to Collection

Article Oncology

Detection of Ovarian Cancer through Exhaled Breath by Electronic Nose: A Prospective Study

Francesco Raspagliesi et al.

CANCERS (2020)

Add to Collection

Review Oncology

Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis

Domenica Lorusso et al.

TUMORI JOURNAL (2019)

Add to Collection

Article Obstetrics & Gynecology

RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy

Giorgio Bogani et al.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

R. L. Coleman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

I. Ray-Coquard et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Pharmacology & Pharmacy

Rucaparib: a new treatment option for ovarian cancer

Ilaria Sabatucci et al.

EXPERT OPINION ON PHARMACOTHERAPY (2018)

Add to Collection

Review Chemistry, Medicinal

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy

Domenica Lorusso et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2018)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

K. Moore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Pharmacology & Pharmacy

The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer

Domenica Lorusso et al.

EXPERT OPINION ON DRUG SAFETY (2017)

Add to Collection

Article Medicine, General & Internal

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman et al.

LANCET (2017)

Add to Collection

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Eric Pujade-Lauraine et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M. R. Mirza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Oncology

Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology

Yvonne Collins et al.

GYNECOLOGIC ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Jonathan Ledermann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Review Oncology

The role of PARP in DNA repair and its therapeutic exploitation

M. Javle et al.

BRITISH JOURNAL OF CANCER (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.